ANAVEX LIFE SCIENCES CORP. Quarterly Common Stock, Shares Authorized from Q3 2010 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Anavex Life Sciences Corp. quarterly Common Stock, Shares Authorized history and growth rate from Q3 2010 to Q2 2024.
  • Anavex Life Sciences Corp. Common Stock, Shares Authorized for the quarter ending June 30, 2024 was 200M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 200M 0 0% Jun 30, 2024 10-Q 2024-08-06
Q1 2024 200M 0 0% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 200M 0 0% Dec 31, 2023 10-Q 2024-02-07
Q3 2023 200M 0 0% Sep 30, 2023 10-Q 2024-08-06
Q2 2023 200M 0 0% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 200M 0 0% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 200M 0 0% Dec 31, 2022 10-Q 2023-02-07
Q3 2022 200M 0 0% Sep 30, 2022 10-K 2023-11-27
Q2 2022 200M 0 0% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 200M +100M +100% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 200M +100M +100% Dec 31, 2021 10-Q 2022-02-09
Q3 2021 200M +100M +100% Sep 30, 2021 10-K 2022-11-28
Q2 2021 200M +100M +100% Jun 30, 2021 10-Q 2021-08-12
Q1 2021 100M 0 0% Mar 31, 2021 10-Q 2021-05-13
Q4 2020 100M 0 0% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 100M 0 0% Sep 30, 2020 10-K 2021-11-24
Q2 2020 100M 0 0% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 100M 0 0% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 100M 0 0% Dec 31, 2019 10-Q 2020-02-06
Q3 2019 100M 0 0% Sep 30, 2019 10-K 2020-12-28
Q2 2019 100M 0 0% Jun 30, 2019 10-Q 2019-08-07
Q1 2019 100M 0 0% Mar 31, 2019 10-Q 2019-05-09
Q4 2018 100M 0 0% Dec 31, 2018 10-Q 2019-02-07
Q3 2018 100M 0 0% Sep 30, 2018 10-K 2019-12-16
Q2 2018 100M 0 0% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 100M 0 0% Mar 31, 2018 10-Q 2018-05-10
Q4 2017 100M 0 0% Dec 31, 2017 10-Q 2018-02-07
Q3 2017 100M 0 0% Sep 30, 2017 10-K/A 2019-01-25
Q2 2017 100M 0 0% Jun 30, 2017 10-Q 2017-08-07
Q1 2017 100M 0 0% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 100M 0 0% Dec 31, 2016 10-Q 2017-02-07
Q3 2016 100M 0 0% Sep 30, 2016 10-K 2017-12-11
Q2 2016 100M -300M -75% Jun 30, 2016 10-Q 2016-08-11
Q1 2016 100M -300M -75% Mar 31, 2016 10-Q 2016-05-11
Q4 2015 100M -50M -33.3% Dec 31, 2015 10-Q 2016-02-08
Q3 2015 100M 0 0% Sep 30, 2015 10-K 2016-12-14
Q2 2015 400M +250M +167% Jun 30, 2015 10-Q 2015-08-14
Q1 2015 400M +250M +167% Mar 31, 2015 10-Q 2015-05-14
Q4 2014 150M 0 0% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 100M -50M -33.3% Sep 30, 2014 10-K 2015-12-29
Q2 2014 150M 0 0% Jun 30, 2014 10-Q 2014-08-13
Q1 2014 150M 0 0% Mar 31, 2014 10-Q/A 2014-05-30
Q4 2013 150M 0 0% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 150M 0 0% Sep 30, 2013 10-K 2014-12-29
Q2 2013 150M 0 0% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 150M 0 0% Mar 31, 2013 10-Q 2013-05-17
Q4 2012 150M 0 0% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 150M 0 0% Sep 30, 2012 10-K 2013-12-30
Q2 2012 150M -1.35B -90% Jun 30, 2012 10-Q 2012-08-17
Q1 2012 150M Mar 31, 2012 10-Q 2012-05-15
Q4 2011 150M Dec 31, 2011 10-Q 2012-02-14
Q3 2011 150M 0 0% Sep 30, 2011 10-K 2012-12-31
Q2 2011 1.5B Jun 30, 2011 10-Q 2011-08-12
Q3 2010 150M Sep 30, 2010 10-K 2011-12-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.